Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-12 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
16/09/26	SEK 0.4595	+0.11%	851,102
15/09/26	SEK 0.4590	-1.18%	2,906,802
14/09/26	SEK 0.4645	-1.28%	2,432,120
11/09/26	SEK 0.4705	-49.79%	14,424,697
10/09/26	SEK 0.9370	+3.31%	1,107,793

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Delayed Nasdaq Stockholm 11:42:38 16/09/2026 +03			5-day change	1st Jan Change
0.4595 ^SEK	+0.11%		-49.34%	-44.57%

09-11	Stockholm stocks ended Friday higher	FW
09-11	Calendar Monday September 14 - Friday September 18	FW

Market Cap	93.01M 9.52M 8.24M 7.79M 7.06M 13.24M 913M 13.34M 35.78M 463M 35.74M 34.95M 1.48B	P/E 2026 *	-1.7x	P/E 2027 *	-1.21x
Enterprise Value	77.01M 7.88M 6.82M 6.45M 5.84M 10.97M 756M 11.05M 29.63M 383M 29.6M 28.94M 1.22B	EV / Sales 2026 *	2.46x	EV / Sales 2027 *	-
Free-Float	75.07%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ALZ	Delayed
Deutsche Boerse AG	78D	Delayed
Börse Stuttgart	78D	Delayed
CBOE		Real-time
CBOE		Real-time

09-11	Stockholm stocks ended Friday higher	FW
09-11	Calendar Monday September 14 - Friday September 18	FW
09-11	Alzinova: Redeye cuts justified value to SEK 0.90	FW
09-11	Asker plunges on double downgrade, OMXS30 index up 0.3 percent	FW
09-11	Asker plunges on choppy Stockholm market	FW
09-11	Stockholm's stock exchange is expected to open Friday on a mixed note	FW
09-11	Alzinova Resolves On Rights Issue Of SEK 51 Mln	RE
09-11	Alzinova Starts Preparations for Mid-stage Trial of Alzheimer's Disease Vaccine Candidate	MT
09-10	Alzinova AB Initiates Operational Start-Up Of Global Phase 2 Study With ALZ-101	CI
08-20	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
08-20	Alzinova reports reduced operating loss	FW
08-20	Calendar Thursday, August 20	FW

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news: Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

09-11	Alzinova: Phase II study update and SEK51 rights issue	AQ
09-11	Alzinova: ALZ-101 enters Phase II start-up as Alzinova raises capital	AQ
09-10	The Board of Directors of Alzinova resolves on a rights issue of units of approximately SEK 51 million	AQ
09-10	Alzinova initiates operational start-up of global Phase 2 study with ALZ-101	AQ
08-24	Alzinova: Diagnostics readout next, partner process delayed – Q2 review	AQ

1 day	+0.11%
1 week	-49.34%
Current month	-42.56%
1 month	-51.53%
3 months	-3.87%
6 months	-31.93%
Current year	-44.57%

1 week	0.45	0.94
1 month	0.45	1.04
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	+0.11%	-49.34%	-59.90%	-85.25%	9.52M
LONZA GROUP AG	+0.52%	+0.48%	-1.49%	+27.41%	45.81B
REVOLUTION MEDICINES, INC.	-0.12%	-1.19%	+343.42%	+545.03%	43.91B
IQVIA HOLDINGS INC.	+1.51%	+4.04%	+45.01%	+27.38%	44.39B
BEONE MEDICINES AG	-2.07%	-1.42%	+4.28%	+72.97%	39.4B
CELLTRION, INC.	-0.73%	-3.06%	+9.63%	+38.92%	31.26B
ASCENDIS PHARMA A/S	-9.49%	-11.23%	-	-	15.75B
MEDPACE HOLDINGS, INC.	+4.21%	+5.01%	+24.99%	+121.62%	17.32B
EUROFINS SCIENTIFIC SE	+0.08%	+3.69%	+17.43%	+33.70%	14.73B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.08%	-2.81%	+79.24%	+31.27%	13.03B
Average	-0.60%	-5.91%	+51.40%	+90.34%	26.56B
Weighted average by Cap.	-0.36%	-1.23%	+76.85%	+134.09%

	2026 *	2027 *
Net sales	31.35M 3.21M 2.78M 2.63M 2.38M 4.46M 308M 4.5M 12.06M 156M 12.05M 11.78M 498M	-
Net income	-4.45M -455K -394K -373K -338K -634K -43.67M -638K -1.71M -22.14M -1.71M -1.67M -70.62M	-77M -7.88M -6.82M -6.45M -5.84M -10.96M -756M -11.05M -29.62M -383M -29.59M -28.93M -1.22B
Net Debt	-16M -1.64M -1.42M -1.34M -1.21M -2.28M -157M -2.3M -6.16M -79.62M -6.15M -6.01M -254M	-19M -1.94M -1.68M -1.59M -1.44M -2.71M -186M -2.73M -7.31M -94.55M -7.3M -7.14M -302M